V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Biolife Solutions Executive Compensation (FY24)

BLFS · Executive and director compensation, fiscal 2022 to 2024
Data as of September 7, 2026Latest filing (8-K): August 21, 2025
209 figures on this page: 203 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Companies named in the disclosed peer group include AngioDynamics, Artivion, Atrion Corporation, Avid Bioservices and Axogen Corporation, among others. Separately, Roderick de Greef was paid $7,046,205 in total compensation as Chief Executive Officer and Chairman of the Board for fiscal 2024, and de Greef's total was 32.5% higher than the $5,316,798 reported for fiscal 2023, while the company reported a chief executive pay ratio of 58:1 for fiscal 2024, against median employee compensation of $122,390. Shareholders supported the say-on-pay proposal with 94.7% of votes cast including abstentions in favor at the meeting held August 20, 2025 for fiscal 2024.
Chief executive, fiscal 2024
◇
Roderick de Greef
Median of the other named officers
$1,515,139
5 officers, excluding the chief executive
Latest say-on-pay support
=
August 20, 2025
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Roderick de Greef: $5,316,798 → $7,046,205 (32.5% higher)
Say-on-pay support: 86.3% → 94.7% (8.4 points higher)
CEO pay ratio: 72:1 → 58:1 (19.4% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Biolife Solutions' chief executive and what were they paid?
Roderick de Greef was paid $7,046,205 in total compensation as Chief Executive Officer and Chairman of the Board for fiscal 2024. De Greef's total was 32.5% higher than the $5,316,798 reported for fiscal 2023.
What was Biolife Solutions' say-on-pay result?
Shareholders supported the say-on-pay proposal with 94.7% of votes cast including abstentions in favor at the meeting held August 20, 2025 for fiscal 2024.
Which companies are in Biolife Solutions' peer group?
Companies named in the disclosed peer group include AngioDynamics, Artivion, Atrion Corporation, Avid Bioservices and Axogen Corporation, among others.
What is Biolife Solutions' chief executive pay ratio?
The company reported a chief executive pay ratio of 58:1 for fiscal 2024, against median employee compensation of $122,390.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Roderick de Greef
Chief Executive Officer and Chairman of the Board
◇—◇—◇——◇
Troy Wichterman
Chief Financial Officer
◇—◇—◇—◇◇
Aby Mathew
Executive Vice President and Chief Scientific Officer
◇◇◇———◇◇
Karen Foster
Chief Quality and Operations Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Roderick de Greef
Chief Executive Officer and Chairman of the Board
◇◇◇———◇◇
Troy Wichterman
Chief Financial Officer
◇—◇———◇◇
Aby Mathew
Executive Vice President and Chief Scientific Officer
◇—◇———◇◇
Karen Foster
Chief Quality and Operations Officer
◇—◇———◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Roderick de Greef
Chief Executive Officer and Chairman of the Board
◇—◇—◇—◇◇
Troy Wichterman
Chief Financial Officer
◇—◇—◇—◇◇
Aby Mathew
Executive Vice President and Chief Scientific Officer
◇—◇—◇—◇◇
Karen Foster
Chief Quality and Operations Officer
◇—◇—◇—◇◇
Garrie Richardson
Former Chief Revenue Officer
Departed during or after this year
◇—◇———◇◇
Todd Berard
Chief Commercial Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Aby J. MathewPSU◇— withheld— withheld—◇—◇
Aby J. MathewPSU◇— withheld◇—◇—◇
Garrie RichardsonPSU◇— withheld— withheld—◇—◇
Garrie RichardsonPSU◇— withheld◇—◇—◇
Karen FosterPSU◇— withheld— withheld—◇—◇
Karen FosterPSU◇— withheld◇—◇—◇
Roderick de GreefPSU◇◇◇—◇—◇
Roderick de GreefPSU◇—◇—◇—◇
Todd BerardPSU◇— withheld— withheld—◇—◇
Todd BerardPSU◇— withheld◇—◇—◇
Troy WichtermanPSU◇— withheld◇—◇—◇
Troy WichtermanPSU◇— withheld— withheld—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Karen FosterOption◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Todd BerardRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Aby MathewRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Troy WichtermanRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Roderick de GreefPSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Amy DuRoss
◇◇————◇
Joydeep Goswami
◇◇————◇
Rachel Ellingson
◇◇————◇
Joseph Schick
◇◇————◇
Cathy Coste, Roderick de Greef, Tony Hunt and Timothy Moore served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • AngioDynamics ANGO
  • Artivion AORT
  • Atrion Corporation ATRI
  • Avid Bioservices CDMO
  • Axogen Corporation AXGN
  • Azenta AZTA
  • Cerus Corporation CERS
  • Codexis CDXS
  • Cryoport CYRX
  • FW Cook symbol not shown
  • Glaukos GKOS
  • iRhythm IRTC
  • MaxCyte MXCT
  • Mesa Laboratories, Inc. MLAB
  • Nanostring Technologies, Inc. symbol not shown
  • NEVRO Corporation NVRO
  • Seres Therapeutics MCRB
  • Silk Road Medical, Inc. SILK
  • STAAR Surgical Company STAA
  • Standard BioTools LAB
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024August 20, 2025=◇◇◇
2023August 1, 2024=◇◇◇
2022July 21, 2023=◇◇◇
2021June 9, 2022=◇◇◇
2020June 18, 2021=◇◇◇
2019July 9, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Biolife Solutions files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Biolife Solutions disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Biolife Solutions sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Biolife Solutions' disclosed peer group is defensible, who names Biolife Solutions back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
209 figures on this page: 203 cited to the filing that reported them, 6 calculated from figures it prints.
203 cited to the filing
6 calculated from the filing

Documents cited

  1. 0000834365-25-000018
  2. 0000834365-25-000007
    AND DIRECTOR COMPENSATION · Grants of Plan-Based Awards
  3. 0001628280-24-035254
  4. 0001628280-24-026862
    Summary compensation table
  5. 0001628280-23-025959
  6. 0001437749-23-016770
    Summary Compensation Table · Summary compensation table
  7. 0001437749-22-015066
  8. 0001437749-21-015556
  9. 0001437749-20-015117
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Biolife Solutions executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/BLFS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Biolife Solutions and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Biolife Solutions discloses

The companies named in BLFS's own disclosed peer group.

AngioDynamicsArtivionAxogen CorporationAzentaCryoportGlaukosiRhythmSeres TherapeuticsSTAAR Surgical CompanyStandard BioTools

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy